. 2017 Nov 6;8(62):105472–105478. doi: 10.18632/oncotarget.22295

Table 3. The effects of VEGFA rs833061 polymorphism on ORR, DCR and PFS among CRC patients receiving bevacizumab treatment.

Genotypes	ORR				DCR				PFS
Genotypes	OR	P	OR^a	P^a	OR	P	OR^a	P^a	HR	P	HR^b	P^b
TT	0.220 (0.044-1.103)	0.048	0.224 (0.044-1.134)	0.071	0.129 (0.031-0.532)	0.002	0.124 (0.030-0.519)	0.004	0.299 (90.141-0.634)	0.002	0.299 (0.141-0.634)	0.002
TC	0.159 (0.029-0.861)	0.021	0.159 (0.029-0.871)	0.034	0.241 (0.054-1.070)	0.052	0.230 (0.051-1.038)	0.056	0.449 (0.203-0.991)	0.048	0.449 (0.203-0.991)	0.048
CC	Reference				Reference				Reference

Notes: a: calculated by logistic regression analysis; b: analyzed by cox-regression analysis.